Ernexa Therapeutics (ERNA) Competitors $1.12 -0.01 (-0.88%) Closing price 04:00 PM EasternExtended Trading$1.10 -0.03 (-2.23%) As of 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ERNA vs. PYRGF, IMA, KLTO, MURA, MRSN, SNTI, RANI, DYAI, XFOR, and JATTShould you be buying Ernexa Therapeutics stock or one of its competitors? The main competitors of Ernexa Therapeutics include PyroGenesis Canada (PYRGF), ImageneBio (IMA), Klotho Neurosciences (KLTO), Mural Oncology (MURA), Mersana Therapeutics (MRSN), Senti Biosciences (SNTI), Rani Therapeutics (RANI), Dyadic International (DYAI), X4 Pharmaceuticals (XFOR), and JATT Acquisition (JATT). These companies are all part of the "pharmaceutical products" industry. Ernexa Therapeutics vs. Its Competitors PyroGenesis Canada ImageneBio Klotho Neurosciences Mural Oncology Mersana Therapeutics Senti Biosciences Rani Therapeutics Dyadic International X4 Pharmaceuticals JATT Acquisition Ernexa Therapeutics (NASDAQ:ERNA) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment. Does the media prefer ERNA or PYRGF? In the previous week, Ernexa Therapeutics had 1 more articles in the media than PyroGenesis Canada. MarketBeat recorded 1 mentions for Ernexa Therapeutics and 0 mentions for PyroGenesis Canada. Ernexa Therapeutics' average media sentiment score of 1.91 beat PyroGenesis Canada's score of 0.00 indicating that Ernexa Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Ernexa Therapeutics Very Positive PyroGenesis Canada Neutral Is ERNA or PYRGF more profitable? PyroGenesis Canada has a net margin of -115.14% compared to Ernexa Therapeutics' net margin of -7,652.75%. Company Net Margins Return on Equity Return on Assets Ernexa Therapeutics-7,652.75% N/A -682.08% PyroGenesis Canada -115.14%N/A -60.81% Do insiders & institutionals believe in ERNA or PYRGF? 70.6% of Ernexa Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are owned by institutional investors. 1.5% of Ernexa Therapeutics shares are owned by company insiders. Comparatively, 47.7% of PyroGenesis Canada shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has better earnings and valuation, ERNA or PYRGF? PyroGenesis Canada has higher revenue and earnings than Ernexa Therapeutics. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioErnexa Therapeutics$580K14.81-$44.54M-$8.31-0.13PyroGenesis Canada$9.14M3.36-$21.12M-$0.03-5.47 Which has more risk & volatility, ERNA or PYRGF? Ernexa Therapeutics has a beta of 5.65, meaning that its share price is 465% more volatile than the S&P 500. Comparatively, PyroGenesis Canada has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. SummaryErnexa Therapeutics and PyroGenesis Canada tied by winning 6 of the 12 factors compared between the two stocks. Get Ernexa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ERNA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ERNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ERNA vs. The Competition Export to ExcelMetricErnexa TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.67M$2.55B$5.75B$10.39BDividend YieldN/A54.21%5.75%4.64%P/E Ratio-0.1323.2675.7726.11Price / Sales14.81716.05544.74124.93Price / CashN/A176.2437.5461.24Price / Book2.245.1412.876.30Net Income-$44.54M$32.95M$3.29B$271.03M7 Day Performance-11.81%0.09%-0.26%-0.15%1 Month Performance-21.84%5.04%3.84%6.41%1 Year Performance-92.81%1.02%68.35%28.81% Ernexa Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ERNAErnexa Therapeutics1.214 of 5 stars$1.12-0.9%N/A-93.3%$8.67M$580K-0.1310PYRGFPyroGenesis CanadaN/A$0.19+2.7%N/A-72.3%$36.19M$9.14M-3.2290IMAImageneBio3.2325 of 5 stars$8.52-4.9%$35.50+316.7%-60.8%$36.02M$9.16M-1.1170Positive NewsHigh Trading VolumeKLTOKlotho Neurosciences0.6054 of 5 stars$0.59+0.9%N/AN/A$35.94MN/A-1.31N/ANews CoveragePositive NewsMURAMural Oncology2.1672 of 5 stars$2.07flat$12.00+479.7%-34.7%$35.86MN/A-0.24119MRSNMersana Therapeutics4.1915 of 5 stars$7.21+0.6%$56.60+685.0%-84.6%$35.78M$40.50M-0.49150Positive NewsSNTISenti Biosciences2.973 of 5 stars$1.39+2.2%$8.50+511.5%-51.9%$35.58M$2.56M-0.164Positive NewsRANIRani Therapeutics3.3139 of 5 stars$0.50+2.3%$7.33+1,369.6%-77.7%$35.06M$1.03M-0.55110Positive NewsDYAIDyadic International2.6348 of 5 stars$0.99+2.6%$6.00+505.6%+4.3%$34.94M$3.49M-5.217XFORX4 Pharmaceuticals4.6091 of 5 stars$3.21+7.4%$34.17+964.4%-83.4%$34.11M$2.56M-0.2280Positive NewsJATTJATT AcquisitionN/A$1.92-4.0%N/A-52.6%$33.12MN/A0.003High Trading Volume Related Companies and Tools Related Companies PYRGF Alternatives IMA Alternatives KLTO Alternatives MURA Alternatives MRSN Alternatives SNTI Alternatives RANI Alternatives DYAI Alternatives XFOR Alternatives JATT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ERNA) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ernexa Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ernexa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
